Analyst Upgraded Stocks on the NAS July 2025

July 23, 2025

Analyst Upgrades

Companies are upgraded when at least one analyst has upgraded their view on the stock, therefore increasing its average consensus value. Companies can get upgraded for a number of reasons, including improved future earnings potential due to new contracts, new products, cost savings or restructuring.

NASDAQ

The National Association of Securities Dealers Automated Quotations (Nasdaq) located in New York City, is the most active stock exchange by volume in the United States.

About the Data

This table includes the number of analyst ratings along with the number of buy-hold-sells on the company. A company is included in this list when its mean rating increases from the previous week.

How do you use this table?

Companies that have recently been upgraded tend to have potential for future gains. Use this table as a starting point for more research on these companies. Stocks with analyst coverage also tend to have higher visibility in the marketplace, therefore have the potential to be more liquid. Stocks in this category are generally held for capital appreciation or growth potential.

For an in-depth look at the fundamentals and valuation of each company, try the stockcalc platform free for 30 days.

SymbolNameBuyOutperformHoldUnderperformSellNo OpinionMean RatingPrev Mean LabelMean Label
USAR USA Rare Earth Inc 1 0 0 0 0 0 5.0 0.0 Buy
ESLA Estrella Immunopharma Inc 1 0 0 0 0 0 5.0 0.0 Buy
All data provided as at market close May 28, 2025.

Company Details

USA Rare Earth Inc

USAR:NAS

Buy

1

Mean Rating

5.0

Prev Mean Rating

0.0

Mean Label

Buy

USA Rare Earth Inc is a vertically integrated, domestic rare earth magnet supply chain that supports the state of energy, mobility, and national security in the United States. USARE is developing an NdFeB magnet manufacturing plant in the United States, and establishing domestic rare earth and critical minerals supply, extraction, and processing capabilities to both supply its manufacturing plant and market surplus materials to third parties.

Access the stockcalc valuation


Estrella Immunopharma Inc

ESLA:NAS

Buy

1

Mean Rating

5.0

Prev Mean Rating

0.0

Mean Label

Buy

Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.

Access the stockcalc valuation


Analysts upgraded USA Rare Earth and Estrella Immunopharma on the NAS this month. See the full list of analyst upgrades on the blog: https://www.stockcalc.com/Blog/analyst-upgraded-stocks-nas-july-2025
USA Rare Earth $USAR and Estrella Immunopharma $ESLA upgraded on the #NAS this month. See the full list of upgrades: https://www.stockcalc.com/Blog/analyst-upgraded-stocks-nas-july-2025
Analysts upgraded USA Rare Earth and Estrella Immunopharma on the NAS this month. See the full list of analyst upgrades on the blog: https://www.stockcalc.com/Blog/analyst-upgraded-stocks-nas-july-2025

Copyright © 2016- Patchell Brook Equity Analytics Inc. All rights reserved.

Risk Disclosure: Equities trading and trading of all markets, exchanges and instruments contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Risk capital is money that can be lost without jeopardizing ones’ financial security or life style. Only risk capital should be used for trading and only those with sufficient risk capital should consider trading. Past performance is not necessarily indicative of future results. View full risk information here.